Evaluation of depth of response within a volumetric model in patients with metastatic colorectal cancer: results of the SIRFLOX study

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter V. Heinemann
Citation Annals of Oncology (2016) 27 (2): 118-128. 10.1093/annonc/mdw198
Authors V. Heinemann1, G. van Hazel2, N. Sharma3, M. Findlay4, J. Ricke5, M. Peeters6, V. Gebski7, M. Van Buskirk8, P. Gibbs9
  • 1Comprehensive Cancer Center, Krebszentrum München, München, Germany, /
  • 2University of Western Australia, Perth, Australia, /
  • 3University of Maryland Medical Center, Bel Air, Maryland, USA, /
  • 4Cancer Trials New Zealand, Auckland, New Zealand, /
  • 5University Clinic Magdeburg, Magdeburg, Germany, /
  • 6Antwerp University Hospital, Edegem, Belgium, /
  • 7NHMRC Clinical Trials Centre, Camperdown, Australia, /
  • 8Data Reduction LLC, Chester, New Jersey, USA, /
  • 9Royal Melbourne Hospital, Melbourne, Australia, /


Depth of Response (DpR) has been proposed as a measure of efficacy that predicts the long-term treatment outcome for patients with metastatic colorectal cancer (mCRC). DpR is a continuous measure that defines the nadir of tumour response, typically by the sum of the longest diameters of all target lesions compared to baseline. There are limited data on the value of applying DpR to clinical trial results, and there is a lack of data relating DpR to baseline tumour load. In the present analysis we applied a volumetric model to the independent blinded reader RECIST data from SIRFLOX. This study was a multicentre randomised controlled trial of 530 patients with non-resectable, liver-only or liver-dominant mCRC that compared first-line mFOLFOX6 (+ bevacizumab at the investigators' discretion) plus selective internal radiation therapy (SIRT) using Y-90 resin microspheres (SIR-Spheres; Sirtex, Sydney, Australia) to mFOLFOX6 (± bev) alone (Control).